# Celcuity Inc. (CELC) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $69.72, market value $3.4 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Celcuity Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Free-cash-flow yield: -5.6%** (5-yr avg -12.7%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -176.1%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -33.9%**. Earnings per share fell 33.9%.

## Financial health
- **Debt to equity: 1.37**. Debt is 1.37 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Current ratio: 10.55** (quick 10.55). Current assets cover the next year's liabilities 10.55 times.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Celcuity Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (13 analysts). 13 analysts cover Celcuity Inc.; the consensus is strong_buy, with an average price target of $154.72 (+122% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -13.1%** (YTD -32.8%, 3-mo -23.5%). The shares are down 13.1% over twelve months including dividends.
- **From 52-week high: -53.8%** (30.2% above the low). Trading 54% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 45**. An RSI of 45 is neutral.
- **Beta (1 yr): 1.25** (volatility 63%). Beta of 1.25 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CELC · Page: https://foliofundamentals.com/stocks/celc

Not investment advice.